Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

European Journal of Cancer - Tập 46 - Trang 340-347 - 2010
Shivaani Kummar1, Martin E. Gutierrez1, Erin R. Gardner2, Xiaohong Chen1, William D. Figg1, Maria Zajac-Kaye1, Min Chen1, Seth M. Steinberg1, Christine A. Muir1, Mary Ann Yancey1, Yvonne R. Horneffer1, Lamin Juwara2, Giovanni Melillo2, S. Percy Ivy3, Maria Merino1, Len Neckers1, Patricia S. Steeg1, Barbara A. Conley1, Giuseppe Giaccone1, James H. Doroshow1,3
1Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
2Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, Frederick, MD 21702, USA
3Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

European Journal of Cancer

Tập 46

340-347

Thông tin tác giả